A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Chawla

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma'. Together they form a unique fingerprint.

Medicine & Life Sciences